Fig S2 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Di Giacomo, Anna Maria; Chiarion-Sileni, Vanna; Del Vecchio, Michele; Ferrucci, Pier Francesco; Guida, Michele; Quaglino, Pietro; Guidoboni, Massimo; Marchetti, Paolo; Cutaia, Ornella; Amato, Giovanni; Covre, Alessia; Camerini, Roberto; Calabrò, Luana; Valente, Monica; Giannarelli, Diana; Mandalà, Mario; Maio, Michele

doi:10.1158/1078-0432.22480140.v1

10780432ccr211046-sup-262709_2_supp_7140470_qtmch1.pdf (145.96 kB)

Fig S2 from Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

journal contribution

posted on 2023-03-31, 22:40 authored by Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Ornella Cutaia, Giovanni Amato, Alessia Covre, Roberto Camerini, Luana Calabrò, Monica Valente, Diana Giannarelli, Mario Mandalà, Michele Maio

Swimmer plot analysis of NIBIT-M2 patients. Swimmer plot showing by study arm patients who at the time of data cut-off were alive and either still on study therapy (n=7) or off study therapy without having received subsequent treatment (n=6), and all patients who had received subsequent treatment at the time of data cut-off, regardless of whether alive or dead (n=32). Patients excluded from the plot (n=31) died without receiving any subsequent therapy.

Funding

AIRC

History

ARTICLE ABSTRACT

Phase II trials have shown encouraging activity with ipilimumab plus fotemustine and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary analysis and 4-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens with fotemustine in patients with melanoma with brain metastases. This phase III study recruited patients 18 years of age and older with BRAF wild-type or mutant melanoma, and active, untreated, asymptomatic brain metastases from nine centers, randomized (1:1:1) to fotemustine, ipilimumab plus fotemustine, or ipilimumab plus nivolumab. The primary endpoint was overall survival (OS). From January, 2013 to September, 2018, 27, 26, and 27 patients received fotemustine, ipilimumab plus fotemustine, and ipilimumab plus nivolumab. Median OS was 8.5 months [95% confidence interval (CI), 4.8–12.2] in the fotemustine arm, 8.2 months (95% CI, 2.2–14.3) in the ipilimumab plus fotemustine arm (HR vs. fotemustine, 1.09; 95% CI, 0.59–1.99; P = 0.78), and 29.2 months (95% CI, 0–65.1) in the ipilimumab plus nivolumab arm (HR vs. fotemustine, 0.44; 95% CI, 0.22–0.87; P = 0.017). Four-year survival rate was significantly higher for ipilimumab plus nivolumab than fotemustine [(41.0%; 95% CI, 20.6–61.4) vs. 10.9% (95% CI, 0–24.4; P = 0.015)], and was 10.3% (95% CI, 0–22.6) for ipilimumab plus fotemustine. In the fotemustine, ipilimumab plus fotemustine, and ipilimumab plus nivolumab arms, respectively, 11 (48%), 18 (69%), and eight (30%) patients had treatment-related grade 3 or 4 adverse events, without treatment-related deaths. Compared with fotemustine, ipilimumab plus nivolumab significantly improved overall and long-term survival of patients with melanoma with asymptomatic brain metastases.